Fig. 1: Generation of mCAR-T cells targeting the TCR-Vβ2 chain.
From: Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
a TRBV usage frequency in CTCL cells from 72 patients seen at the Yale Photopheresis Unit from 2016 to 2022 as determined by anti-Vβ antibody staining (Beckman Coulter IOTest Beta Mark) and flow cytometry. b Distribution of TRBV frequency in total CD4 T cells from a Vβ2+ Sézary Syndrome (SS) patient determined by anti-Vβ antibody set staining and flow cytometry (top) or by paired single cell mRNA/TCR sequencing (bottom13,). c Live CTCL cell counts from three Vβ2+ and one Vβ13.2 + CTCL patients after overnight in vitro culture with allogeneic mCAR-Vβ2 T cells with (right) or without (left) knockout (KO) of the endogenous T cell receptor alpha constant (TRAC) region at different effector-to-target (E:T) ratios, as determined by flow cytometry. d, e Live fraction of Vβ2+ CTCL cells or normal Vβ2+ cells (red), Vβ2- normal T cells (blue), and non-T cells (black) from PBMC of two Vβ2+ CTCL patients (d) and healthy control (HC)1 (e) at different E:T ratios after overnight co-culture with allogeneic triple KO (TRAC/B2M/CIITA) mCAR-Vβ2 T cells, as determined by flow cytometry. f Live fraction of each detectable Vβ subtype+ cells from total T cells of HC2 at different E:T ratios after overnight co-culture with allogeneic triple KO mCAR-Vβ2 T cells, as determined by flow cytometry. c–f N = 3 replicates of each E:T condition. Data are presented as mean values +/− SEM. *p < 0.05, **p < 0.01 and ****p < 0.0001 by two-way ANOVA. All replicates are independent samples. Source data and exact p-values are provided as a Source Data file.
